Abstract
Introduction Voluntary Medical Male Circumcision (VMMC) is a cost-effective HIV prevention strategy that reduces the risk of female-to-male transmission by approximately 60%. Mozambique has implemented a national VMMC program since 2010, including HIV testing to identify HIV-positive men. We used program data to describe the President’s Emergency Plan for AIDS Relief (PEPFAR)-supported VMMC services in seven provinces in Mozambique.
Methods We analyzed aggregate PEPFAR Monitoring, Evaluation, and Reporting data for 2010–2023 for VMMCs conducted and HIV testing at VMMC sites. Per the Population-Based HIV Impact Assessments conducted in Mozambique in 2021 (PHIA 2021), the VMMC coverage rate was obtained from the above survey, which accounted for responses from males who reported medical or traditional circumcisions in national surveys over the estimated population.3 Test positivity rate was calculated as positive tests over the total tests conducted. Data were analyzed by fiscal year (October–September), age group (<15 years, 15–29 years, ≥30 years), and province.
Results During 2010-2023, a total of 2,534,411 VMMCs were performed, of which 1,032,789 (41%) were among boys <15 years old, 1,368,582 (54%) among men aged 15–29, and 133,039 (5%), men aged >30. By 2023, national VMMC coverage was 77% (higher among men aged 20–24 years, at 80%). Overall HIV test positivity rate among VMMC clients was 1.6% (35,743 positives), ranging from 0.4% to 5.9% across provinces. Older men aged 45-49 had a higher HIV positivity rate of 24.3%.
Conclusion VMMC implementation over twelve years reached priority boys and men aged 15-29 for immediate impact on HIV prevention. Essentially, the program has circumcised many boys and men, leading to higher VMMC coverage and anticipated reductions in HIV transmission. Further, services have helped identify men already living with HIV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the U.S. Centers for Disease Control and Prevention (CDC). The findings and conclusions in this manuscript are those of the author(s) and do not necessarily represent the official position of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used PEPFAR Monitoring, Evaluation, and Reporting program.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available from PEPFAR Monitoring, Evaluation, and Reporting program data.
